KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Tax Provisions (2018 - 2025)

Moderna (MRNA) has disclosed Tax Provisions for 8 consecutive years, with $27.0 million as the latest value for Q4 2025.

  • Quarterly Tax Provisions rose 142.19% to $27.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $54.0 million through Dec 2025, up 217.39% year-over-year, with the annual reading at $54.0 million for FY2025, 217.39% up from the prior year.
  • Tax Provisions for Q4 2025 was $27.0 million at Moderna, up from $13.0 million in the prior quarter.
  • The five-year high for Tax Provisions was $1.7 billion in Q3 2023, with the low at -$384.0 million in Q1 2023.
  • Average Tax Provisions over 5 years is $161.9 million, with a median of $27.0 million recorded in 2025.
  • The sharpest move saw Tax Provisions surged 27000.0% in 2021, then crashed 233.21% in 2023.
  • Over 5 years, Tax Provisions stood at $542.0 million in 2021, then tumbled by 64.94% to $190.0 million in 2022, then crashed by 177.37% to -$147.0 million in 2023, then soared by 56.46% to -$64.0 million in 2024, then soared by 142.19% to $27.0 million in 2025.
  • According to Business Quant data, Tax Provisions over the past three periods came in at $27.0 million, $13.0 million, and $7.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.